Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The primary objective of the study is to assess the cardiac status of COVID-19 pneumonia patients during 1 year after discharge
Description: Echocardiographic assessment of global strain parameters at 3 and 12 months after discharge
Measure: Echocardiographic assessment of cardiac function Time: up to one yearDescription: Major adverse cardiac and cerebrovascular events: cardiac death, myocardial infarction, or stroke at 3 and 12 months after discharge
Measure: МАССЕ Time: up to one yearDescription: Describe the parenchymal lung damage through a quantitative analysis with chest CT at 3 and 12 months after discharge
Measure: Quantitative analysis of parenchymal lung damage Time: up to one yearDescription: Six-min walk test at 3 and 12 months after discharge
Measure: Functional exercises capacity assessment Time: up to one yearDescription: Measure of creatinine clearance at 3 and 12 months after discharge
Measure: Evaluation of renal function Time: up to one yearDescription: Analysis for C-reactive protein at 3 and 12 months after discharge
Measure: Evaluation of inflammation Time: up to one yearDescription: Analysis for activated clotting time at 3 and 12 months
Measure: Evaluation of coagulation abnormality Time: up to one yearDescription: Assessment of the Short Form Health Survey (SF36) at 3 and 12 months after discharge
Measure: Evaluation of quality of life in first year after discharge Time: up to one year